Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 765049 ± ezabenlimab in B7-H6+ solid tumors
NCT04752215Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2021
- Primary completion
- Nov 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of BI 765049 in colorectal cancer (CRC), non-small cell lung cancer (NSCLC), pancreatic cancer (PC) and 3 more (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Tolerated Dose at 3 weeks and Dose Limiting Toxicities at 3 weeks. Started May 2021; status: completed.
02
Drugs
BI 765049
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)pancreatic cancer (PC)hepatocellular carcinoma (HCC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04752215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04752215.